Use of Personalized Post-Total Thyroidectomy Criteria in Low and Intermediate Risk Papillary Thyroid Cancer Patients to avoid Routine Radioactive Iodine Administration

Paul G Walfish*
Senior Endocrine Consultant, Canada

Submission: February 12, 2017; Published: March 17, 2017

*Corresponding author: Paul G Walfish, CM, O.Ont., MD, FRCP(C), FACP, FRSM (Engl), FCAHS, Professor Emeritus of Medicine, Pediatrics, Otolaryngology-Head & Neck Surgery, Pathology & Laboratory Medicine, University of Toronto Senior Endocrine Consultant, Joseph and Mildred Sonshine Family Centre for Head & Neck Disease, Alex and Simona Shnaider Research Chair in Thyroid Oncology, Mount Sinai Hospital/Sinai Health Center, 600 University Avenue, Rm., 413-7, Toronto, Ontario, M5G 1X5, Canada, Tel: 416-586-4437; Fax: 416-586-8861; Email: paul.walfish@sinahealthsystem.ca

Mini Review

In the treatment of many types of cancer, clinicians are required to make assessments of patient risk based on a range of factors and then tailor treatment to reflect that level of risk. A recent study from our centre has shown that the use of several personalized criteria in low and intermediate-risk papillary thyroid cancer (PTC) patients after treatment by a total thyroidectomy can avoid routine radioactive iodine remnant ablation (RAI) in the vast majority of such patients.

The Administration of RAI to PTC Patients

Each year an estimated 62,000 people in the US are diagnosed with thyroid cancer [1], a significant percentage of patients undergo total thyroidectomy for a total removal of the thyroid gland and any gross central compartment lymph nodes when indicated. This treatment option has proved to be highly effective for managing most PTC patients when combined with long term serum TSH suppression using thyroxine administration.

To eliminate remaining potential residual normal and or cancer thyroid cells, many PTC patients have been routinely receiving RAI at varying dosages. The American Thyroid Association (ATA) guidelines state that use of remnant ablation involving administration of RAI may be appropriate for many PTC patients, including some low-risk patients [2]. In recent years, there have also been some uncertainty about the benefits of RAI remnant ablation to reduce the risk of recurrence, especially among patients with low-risk papillary thyroid cancer (PTC). We and others have demonstrated that most total thyroidectomy PTC patients can be shown to often have achieved a TSH-stimulated thyroglobulin (Stim-Tg) levels less than 1µg/L before RAI, making the risk for recurrence or death very unlikely [3-7]. Such PTC patients can be safely followed using combined neck ultrasound and serum thyroglobulin levels as a reliable indicator of residual or recurrent PTC when there is no detectable anti thyroglobulin antibody to interfere with the accurate measurement of thyroglobulin. In addition, literature reports have not demonstrated that RAI therapy decreases recurrence rates or risk of death in low-risk PTC patients [8-10].

While ATA guidelines support “selective use” of RAI for low- and intermediate-risk PTC patients, objective criteria to support its use are generally not available [2,11,12]. Lack of clear guidelines and conflicting opinions among clinicians in recent years [13,14] have supported the routine administration of RAI. In light of the lack of data demonstrating a clear benefit from RAI and the potential [16-19] health risks associated with RAI, our center [15] and others have worked to develop a more effective strategy to determine which low and intermediate - risk PTC patients should be treated with RAI [4]. Such personalized criteria are based upon post-operative pathology findings, Stim-Tg and neck ultrasound for each PTC patient in our cohort. Using this protocol, we have demonstrated that this approach can assist in determining which PTC patients may safely avoid routine RAI and select those that may benefit from such therapy.

Research Findings

In our long term prospective research report follow up data at a mean duration of 6.2 years was obtained from low and intermediate-risk PTC patients who previously were treated with a total thyroidectomy [3,4,15]. Low-and intermediate-risk was defined as all PTC nodules equal or greater than 1cm (T1-T3),
confined to the thyroid or central (level VI) lymphnodes (N0-N1a), irrespective of patient age or tumor size. Exclusion criteria included (1) tumors less than 1cm given that their risk for PTC recurrence was defined as very low, (2) detectable anti-thyroglobulin antibodies (TgAb) given their potential interference with the thyroglobulin (Tg) assay, (3) lateral compartment lymph node involvement (N1b) and (4) extra-thyroidal extension (T4) or distant metastases (M1). The study also collected relevant demographic, surgical, pathologic, lab biochemistry, treatment and clinical outcome data [15].

All patients underwent a post-operative stimulated thyroglobulin (Stim-Tg) and neck ultrasound approximately three months after their thyroidectomy [15]. The sub-group of patients with Stim-Tg measurements less than 1µg/L was informed that the thyroidectomy was likely curative and that there was no definite indication for administration of RAI. Patients with Stim-Tg greater than 1µg/L but less than 5µg/L were informed that there was no immediate indication for RAI and could be followed by active surveillance to validate the absence of a risk for residual thyroid cancer by no significant changes in the follow up Stim-Tg and neck ultrasound. However, patients with a Stim-Tg greater than 5µg/L were strongly advised to proceed with RAI therapy [15].

All patients were followed on long-term thyroid hormone TSH-suppression therapy with repeat neck ultrasound and Stim-Tg measurements every 6-12 months. Patients who received RAI had a whole-body scan (WBS) seven days after treatment. A total of 129 low/intermediate-risk PTC patients were followed prospectively for a mean duration of 6.2 years.

Conclusion

Among the 129 PTC patients who were stratified as low/intermediate-risk, 116 (90%) were able to avoid RAI using this strategy with a mean prospective follow-up of 6.2 years and virtually no risk of residual/recurrent disease. (A single patient who had evidence of residual/recurrent disease was correctly identified to receive RAI using this strategy). The overall risk for residual/recurrent PTC was less than 1%, and no patients required RAI at a subsequent two-year follow up to a mean of 8.2 years.

These findings from our center published by Orlov et al. (2008) Basis for physician recommendations for adjuvant radioiodine therapy in low-risk papillary thyroid cancer. J Clin Endocrinol Metab 93(3): 1440-1445. have developed for the improved identification of those PTC patients who can safely avoid RAI. Consequently, this personalized strategy will vary significantly lower the incidence of RAI administration in the vast majority of low and intermediate-risk PTC cohorts after a total thyroidectomy and will also reduce in health care costs, patient inconvenience, and potential radiation exposure side effects.

References

1. American Cancer Society (2016) Key statistics for thyroid cancer.
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. (2015) American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Thyroid 26(1): 1-133.
3. Hall FT, Beasley NJ, Eski SJ, Witterick IJ, Walfish PG, et al. (2003) Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 113(1): 77-81.
4. Vaisman A, Orlov S, Yip J, Hu C, Lim T, et al. (2010) Application of postsurgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32(6): 689-698.
5. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, et al. (2005) Serum thyroglobulin levels at the time of I 131 remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90(3): 1440-1445.
6. Rosario PW, Xavier AC, Calsolari MR (2011) Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and I131 activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21(1): 49-53.
7. Heemstra KA, Liu YY, Stokkel M, Kievet J, Corssmit E, et al. (2007) Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 66(1): 58-64.
8. Sawka AM, Brierley JD, Tsang RW, Thabane L, Röösli L, et al. (2008) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37(2): 457-480.
9. Sawka AM, Thephemongkol K, Brouwers M, Thabane L, Brownman G, et al. (2004) Clinical review 170: a systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89(8): 3668-3676.
10. Sacks W, Fung CH, Chang JT, Waxman A, Brunstein GD (2010) The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 20(11): 1235-1245.
11. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11): 1167-1214.
12. Perros P, Boelaert K, Colley S, Evans C, Evans RM, et al. (2014) Guidelines for the management of thyroid cancer. Clin Endocrinol 81(Suppl 1): 1-122.
13. Hayman MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, et al. (2011) Use of radioactive iodine for thyroid cancer. JAMA 306(7): 721-728.
14. Sawka AM, Goldstein DP, Thabane L, Brierley JD, Tsang RW, et al. (2008) Basis for physician recommendations for adjuvant radioiodine therapy for differentiated thyroid carcinoma.
therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey. Endocr Pract 14(2): 175-184.

15. Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, et al. (2015) Postoperative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low and intermediate-risk papillary thyroid cancer. Endocrine 50(1): 130-137.

16. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, et al. (2011) Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18(2): R29-R40.

17. Rosario PW, Mineiro AF, Prates BS, Silva LC, Calsolari MR (2012) Postoperative stimulated Thyroglobulin less than 1ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22(11): 1140-1143.

18. Webb RC, Howard RS, Stojadinovic A, Gatcombe DY, Wallace MK, et al. (2012) The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 97(8): 2754-2763.

19. Giovannella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, et al. (2014) Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 99(2): 440-447.

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

https://juniperpublishers.com/online-submission.php

This work is licensed under Creative Commons Attribution 4.0 License

DOI: 10.19080/JETR.2017.01.555558

How to cite this article: Paul G W.Use of Personalized Post-Total Thyroidectomy Criteria in Low and Intermediate Risk Papillary Thyroid Cancer Patients to avoid Routine Radioactive Iodine Administration. J Endocrinol Thyroid Res. 2017; 1(2): 555558. DOI: 10.19080/JETR.2017.01.555558